Vaxcyte(NASDAQ) PCVX

Vaxcyte makes vaccines to help people stay healthy and avoid dangerous lung and blood infections. These shots teach the body to recognize and fight off harmful bacteria like those that cause pneumonia. The company builds its medicines using a unique method that allows for more protection in a single dose.

What is Vaxcyte Building?

• VAX-31: Broadest-spectrum vaccine candidate in clinical development; designed to protect against 31 different strains of bacteria that cause invasive disease and pneumonia.
• VAX-24: Investigational 24-valent vaccine; intended to improve upon current standard-of-care shots for infants and adults.
• VAX-A1: Early-stage vaccine candidate; specifically targeting Group A Strep which causes strep throat and severe heart or skin complications.
• VAX-GI: Preclinical treatment for dysentery; designed to stop Shigella bacteria from causing severe intestinal illness.

Growth and Expansion Plans

• Initiated the OPUS-1 Phase 3 trial in December 2025; evaluates VAX-31 in adults compared to current leading vaccines from Pfizer and Merck.
• Signed a long-term agreement with Thermo Fisher Scientific in September 2025; secures up to $1 billion in commercial manufacturing and filling services in North Carolina.
• Obtained exclusive rights from Sutro Biopharma in November 2023; allows for independent control over making the cell-free extract needed for all vaccine candidates.
• Reached a new commercial manufacturing deal with Lonza in October 2023; provides the infrastructure needed to launch products globally if they receive regulatory approval.

Why the Technology is Different

Vaxcyte uses a cell-free platform called XpressCF that builds proteins outside of living cells. This allows the company to attach more bacterial strains to a single vaccine without making the medicine less effective.

The Financial Picture

• Operating income fell to -$274 million in Q4 2025, down 69.1% from the previous year.
• Net income was -$246.5 million in Q4 2025, down 79.8% year-over-year as research costs increased.
• Free cash flow hit -$219.3 million in Q4 2025, down 55% from the year-ago period.
• The company had 414 full-time employees at the end of 2025 to support its expanding clinical trial programs.

Bottom Line

Vaxcyte has transitioned from a research firm to a late-stage clinical company focused on the $8 billion pneumonia vaccine market. By using cell-free technology, it aims to replace older vaccines with broader-spectrum options for all age groups.